The association of neutralizing antibodies with protection against symptomatic dengue virus infection varies by serotype, prior immunity, and assay condition

Sandra Bos[1,#*], Aaron Graber[1,#], Jaime A. Cardona-Ospina[1], Elias Duarte[1], Jose Victor Zambrana[2,3], Jorge Alberto Ruíz Salinas[2], Reinaldo Mercado-Hernandez[1], Tulika Singh[1], Leah Katzelnick[4], Aravinda de Silva[5], Guillermina Kuan[2,6], Angel Balmaseda[2,7], Eva Harris[1*]

[#] These authors contributed equally

*Co-corresponding authors

[1]Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA

[2]Sustainable Sciences Institute, Managua, Nicaragua

[3]Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA

[4]Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

[5]Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA

[6]Centro de Salud Sócrates Flores Vivas, Ministerio de Salud, Managua, Nicaragua

[7]Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua

Abstract

The four dengue virus serotypes (DENV1–4) are the most prevalent arboviruses in humans and a major public health concern worldwide. Identification of the immune mechanisms that modulate DENV infection outcome is critical for development of a safe and effective vaccine. Neutralizing antibodies (nAbs) are considered an essential component of the protective response, yet measurement of their potency is primarily performed using a single cellular substrate and partially mature virions. This approach does not capture the full breadth of neutralizing activity and may lead to biased estimations of nAb potency and repertoire. Here, we evaluated the nAb response associated with protection against dengue cases using samples collected after one or more DENV infections but prior to a subsequent symptomatic versus inapparent DENV1, DENV2 or DENV3 infection from a long-standing pediatric cohort study in Nicaragua. We compared nAb titers in pre-inapparent and pre-symptomatic infection samples in Vero cells with or without DC-SIGN expression, and with either mature or partially mature virions. This method allowed us to measure the magnitude and characteristics of the nAb response associated with outcome and revealed that correlation of nAb titers with protection from symptomatic infection is dependent on the individual's prior DENV immune status as well as the subsequent infecting DENV serotype. Further, the nAb potency and the protective NT_{50} cutoff was greatly impacted by virion maturation state and cell substrate. These results have important implications for determination of antibody correlates of protection for vaccines and natural infections.

Introduction

The four dengue virus serotypes (DENV1-4) are mosquito-borne flaviviruses endemic to tropical and subtropical regions that cause the most prevalent arthropod-borne viral disease in humans. Up to 100 million people are infected each year, of whom approximately 50 million will develop symptoms ranging from self-limiting but debilitating dengue fever to potentially fatal dengue shock syndrome[1]. Infection with one of the four antigenically related DENV serotypes leads to the production of type-specific antibodies, which are specific to the infecting serotype, as well as cross-reactive (XR) antibodies that can bind to other DENV serotypes. These XR antibodies can either provide protection or increase the risk of subsequent symptomatic or severe DENV infection after both natural infections and vaccines[2–5]. The occurrence of such adverse events emphasizes the complexity of DENV immunity and the crucial need for a comprehensive evaluation of correlates of protection to facilitate studies of natural infections and the development of safe and effective DENV vaccines.

Neutralizing antibodies (nAbs) are essential for protection against dengue in both natural infections and vaccine trials[5,6]. There is an increased risk of severe disease during secondary DENV infections, such that pre-existing nAbs from earlier DENV exposures have a crucial role in mitigating disease outcomes. The composition and magnitude of pre-existing nAbs can vary depending on the previous infecting serotype and number of previous infections[2–5]. The current “gold standard" to assess the neutralizing potential of nAbs are Plaque or Focus Reduction Neutralization Tests (PRNT/FRNT), where virus infectivity is measured over a serial dilution of serum/plasma samples[7]. Vaccine trials to evaluate correlates of protection usually perform DENV neutralization assays according to the reference assay conditions with Vero cells as substrate and WHO reference DENV strains grown in either mammalian (Vero) or insect (C6/36) cells. Although higher nAb titers correlate with a reduced risk of dengue disease, symptomatic dengue cases can occur in individuals with relatively high nAb titers, suggesting that the current neutralization assays may not adequately measure the types of nAbs critical for protection[5,6].

The DENV genome encodes three structural proteins -- envelope (E), precursor membrane/membrane (prM/M), and capsid (C) -- that form the virion and seven nonstructural proteins responsible for viral replication, assembly, and immune evasion [8]. Neutralizing antibodies primarily target the envelope (E) protein of the virus, and their potency is influenced by the epitope they target. The epitope itself determines the required amount of antibodies to neutralize a viral particle (stoichiometry), and their efficiency varies depending on viral strains and physiological environment. Thus, several factors, including the temperature of incubation, the maturation state of the virion, the viral strain, and the choice of cell substrate impact the type

of antibody measured. As a result, neutralization assay conditions can modulate nAb potency[9,10] and the ability to measure antibody repertoire and functionality, referred to here as “quality”.

DENV FRNT/PRNTs are commonly performed using DENV laboratory strains grown in Vero cells, which may not reflect the maturation state of virus circulating in human subjects[9]. During viral assembly, immature particles are formed in the endoplasmic reticulum and transported to the extracellular surface through the Golgi network, where they undergo maturation. These immature particles are characterized by a spiky surface formed by trimeric prM-E heterodimers, with pr peptides capping the E fusion loop (FL)[11]. Their transit through the acidic compartment of the Golgi network results in a rearrangement of the E proteins (trimers to dimers), and maturation occurs by cleavage of prM by the host protease furin[12,13]. Upon release into the neutral pH of the extracellular medium, the pr peptides detach, revealing the smooth mature viral progeny that are infectious. However, maturation is not always complete. Areas where pr has not been cleaved revert to trimeric spikes once virions are secreted, creating mosaic particles harboring different organizations of E proteins on their surface[14]. This difference in maturation state changes the proportion and identity of epitopes exposed and, thus, the number and type of antibodies required to completely neutralize infectious viral particles[10,15].

In addition, the cellular substrate of the neutralization assay is an important factor that can influence neutralization potency, as it determines the host receptors relevant for viral entry. Unlike other flaviviruses, the E protein of DENV has an additional glycosylation site at Asp-67 (E domain I), which allows DENV to enter cells through interaction with the DC-SIGN attachment factor[16]. DC-SIGN is expressed on dendritic cells (DCs) and monocytes, which account for the majority of DENV-infected cells in the blood [17–22]. DCs are potent antigen-presenting cells that mediate both innate and adaptive immunity by producing cytokines and transporting antigens to secondary lymphoid organs, where they prime naïve antigen-specific T cells. Nevertheless, *in vitro* studies have shown that while DENV2-infected DCs can undergo activation and release of pro-inflammatory cytokines, they do not secrete IFN-α/β, which is critical for T cell priming[19]. Meanwhile, monocytes facilitate viral dissemination to various peripheral organs by acting as Trojan horses and transporting DENV virions to target tissues[23]. DC-SIGN promoter polymorphism in humans contributes to genetic susceptibility to DENV infection and is a risk factor for developing severe dengue disease. As a result, efficient neutralization in the presence of DC-SIGN is important for limiting viral dissemination and for the establishment of a rapid and effective cell-mediated immune response[19]. Evaluation of DC-SIGN-mediated entry in an FRNT/PRNT assay enables a broad assessment of neutralizing potential of nAbs by measuring

the impact of nAbs that prevent N-glycan interaction and should be considered when investigating immune correlates of protection.

Here, we used a set of plasma samples from our long-standing prospective pediatric dengue cohort study in Nicaragua and evaluated the cross-reactive nAb response prior to subsequent inapparent or symptomatic infections with DENV1, DENV2, and DENV3. We compared neutralization potency across multiple assay conditions using partially mature and mature virions on Vero cells and Vero cells expressing DC-SIGN. Using these four assay conditions, we evaluated the nAb magnitude and quality associated with protection against symptomatic DENV infection. We found that correlation with protection is dependent on the individual's prior DENV immune status and the subsequent infecting serotype, as well as assay conditions. Further, we show that comparison of nAb titers obtained with partially mature versus mature virions and presence or absence of DC-SIGN can indicate the quality of antibodies that are important for protection.

Materials and Methods

Ethics statement

The human subjects protocol for the PDCS was reviewed and approved by the Institutional Review Boards (IRB) of the University of California, Berkeley (2010-09-2245), the University of Michigan (HUM00091606), and the Nicaraguan Ministry of Health (CIRE-09/03/07-008). Parents or legal guardians of all subjects provided written informed consent, and subjects 6 years of age and older provided assent.

Samples and study population

The Pediatric Dengue Cohort Study (PDCS) is an ongoing open prospective cohort of 4,000 children 2-17 years old that was initiated in 2004[2,24]. Blood samples are collected annually, and additional samples are collected from symptomatic suspected dengue cases at the acute (0-6 days post-onset of symptoms) and convalescent (14-21 days post-onset of symptoms) phase. DENV infections are evaluated and recorded yearly by comparing healthy annual serum/plasma samples collected in two consecutive years side-by-side by inhibition enzyme-linked immunosorbent assay (iELISA)[2]. A $\geq$4-fold increase in iELISA titer between annual samples is considered as indication of an infection[25]. We selected 64 pre-inapparent and 63

pre-symptomatic infection plasma samples among DENV-immune participants[2,24] who had experienced one or more prior DENV infections.

Symptomatic dengue cases were confirmed by detection of DENV RNA by RT-PCR, real-time RT-PCR and/or virus isolation in the acute-phase sample; seroconversion of DENV-specific immunoglobulin M antibodies in paired acute- and convalescent-phase samples; or a ≥4-fold increase in antibody titer by iELISA between acute and convalescent sera[2,26–28]. The serotype of symptomatic infections was determined by RT-PCR or real-time RT-PCR[26,29,30]. Inapparent infections were identified with a ≥4-fold increase in iELISA titer among participants who did not present with illness to the study Health Center between annual samplings. In a subset, the serotype responsible for the inapparent infections that occurred before 2016 was identified by neutralization assays (DENV1-4) and/or a multiplex Luminex-based assay (E domain III [EDIII] of DENV1-4 and ZIKV) by comparing the antibody profile in the annual samples collected before and after the infection. Inapparent infections detected in 2016-2019 were attributed to DENV2 based on laboratory and epidemiological data showing the circulation of only DENV2 in Nicaragua during these years.

Cell lines

Vero cells (ATCC CCL-81), Vero cells stably expressing human furin (Vero-Furin; kind gift of Victor Tse and Ralph Baric, University of North Carolina (UNC), Chapel Hill)[31], and Vero cells expressing DC-SIGN (Vero DC-SIGN) were maintained in minimum essential medium (MEM; Gibco) with 5% fetal bovine serum (FBS) supplemented with 1X non-essential amino acids (Gibco), 1X sodium pyruvate (Gibco), and 1X penicillin-streptomycin (Gibco) at 37°C in 5% CO_2.

Generation of Vero DC-SIGN cell line

Vero cells were transduced using lentivirus to express DC-SIGN (CD209). DC-SIGN surface expression was confirmed by flow cytometry using a PE-conjugated mouse anti-CD209 antibody (BD Bioscience) for cell surface staining. A stock of Vero cells expressing surface DC-SIGN receptors at >95% was generated by cell sorting using the BD InfluxTM cell sorter and the BD FACSDivaTM 8.0.1 software (BD Biosciences).

Virus production

DENV1 (5575.10a1SPD1), DENV2 (8891.12a1SPD2) and DENV3 (6629.10a1SPD3) are clinical isolates from Nicaragua, isolated on C6/36 cells and passaged twice in Vero cells prior to production of working stocks. Partially mature and mature viruses were grown in Vero and

Vero-Furin cells, respectively, in the same growth medium described above. Virions were harvested 5 days post-infection and frozen at 80°C until use.

Viral titer

Infectious titers were determined using a standard focus-forming assay[32]. Briefly, Vero and Vero DC-SIGN cells were infected with serial dilutions of virus and incubated at 37°C for 42-48 hours (h) depending on the virus strain. Cells were fixed, permeabilized with 0.5% Triton for 6 minutes, and stained with primary mouse anti-FL monoclonal antibody (mAb) 4G2 for 1.5h, washed 2 times with PBS BSA 1%, and incubated with a goat anti-mouse secondary antibody conjugated to horseradish peroxidase for 1h at room temperature. Foci were developed using True Blue HRP substrate (KPL) and were counted using an CTL Immunospot analyzer (Cellular Technology, Ltd.). The titer in focus forming units (FFU) per ml was then calculated based on the average of replicates.

Viral genome quantification and calculation of infectivity

Viral RNA (vRNA) was extracted from virus particles using the QIAmp kit (QIAGEN). The PCR standard curve used for the quantification of DENV copy genome was obtained with an amplicon containing a synthetic cDNA encompassing a fragment of the 3'UTR region (nucleotides 10361–10660) from DENV2 NI15. Pan-DENV primers (F – TTGAGTAAACYRTGCTGCCTGTAGCTC; R - GAGACAGCAGGATCTCTGGTCTYTC,) were used to amplify the 3'UTR region encompassing nucleotides 10361–10660 of the genome of DENV clinical isolates used in this study. To assess the proportion of infectious viral particles in each of the virus stocks, viral titers obtained in different cell lines were plotted against the number of RNA copies present in each dilution of virus studied. Specific infectivity was calculated as the number of RNA molecules required for each infection event (vRNA:FFU).

Assessment of virion maturation state

For each serotype, equal numbers of vRNA genome equivalents (GE) of partially mature and mature viral stocks were diluted in 6X Laemmli sample buffer, boiled at 95°C for 5 minutes, and subjected to SDS-PAGE electrophoresis on a 4-20% gradient gel. Proteins were then transferred to a PVDF membrane and blocked using a blocking buffer containing 5% non-fat milk in PBS + 0.1% Tween-20 (PBS-T). The membrane was incubated with a purified human anti-E FL mAb (1M7) and anti-prM mAbs (2G3, 1E23 and 2H21) at 0.1ug/ml in blocking buffer at 4°C overnight. Antigen-antibody complexes were detected using donkey anti-human IgG

conjugated to horseradish peroxidase (HRP; 1:5000, Biolegend) in blocking buffer for 1h at room temperature. Membranes were developed in Supersignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher). Western blot images were captured with a ChemiDoc XRS+ system (Bio-Rad). The pixel intensity of individual bands was measured using FIJI software, and relative maturation was calculated by using the following equation: $(prM_{Vero\ Furin}/E_{Vero\ Furin})/(prM_{Vero}/E_{Vero})$.

Neutralization assay

The focus reduction neutralization test (FRNT) assay was conducted using Vero or Vero DC-SIGN cells. Briefly, cells were seeded in a 96-well plate one day before infection. Serum/plasma or mAbs were serially diluted and mixed with an equal inoculum of DENV (equivalent to 40-50 FFU/well for Vero and 150-200 FFU/well for Vero DC-SIGN cells) at a volume ratio of 1:1 to form immune complexes. The virus-antibody mixture was incubated for 1h at 37°C in 5% CO_2. Cell substrate growth medium was removed, and the virus-antibody mixture was added to Vero or Vero DC-SIGN cells and incubated for 1h at 37°C in 5% CO_2. Subsequently, a 0.6% carboxymethylcellulose overlay was added, and the plates were incubated for 48h. Foci were developed and counted as described above. Foci counts were fitted using a variable slope dose response curve using Graphpad, and NT_{50} values were calculated with constrained top and bottom values of 100 and 0, respectively. Percent relative infection was calculated as a ratio of foci counts in each serial dilution to the foci counts from the final serial dilution of each sample. All samples and mAbs were run in duplicate with reported values required to have an $R^2 > 0.85$ and a Hill slope > 0.5.

Statistical analysis

NT_{50} values were obtained using GraphPad software as indicated above. Statistical analysis was performed in R software. Normal distribution of data was tested using the Shapiro-Wilk test. Adjusted p-values and statistical significance of nAb titer magnitude and differential NT_{50} comparisons were computed using the Wilcoxon test with Benjamini Hochberg correction. Adjusted p-values and statistical significance of nAb potency across neutralization assay conditions were computed using the paired Wilcoxon test with Benjamini Hochberg correction to identify changes in antibody quality.

Receiver Operator Curve (ROC) analysis was performed using the pROC package (v.1.18.0) in R studio (v. 2022.12.0+35). The pooled area under the curve (AUC) and sensitivity and specificity of NT_{50} across different assay conditions was estimated to detect a subsequent symptomatic infection. An analysis stratified by incoming serotype was also conducted to

evaluate differential performance of the assay conditions across DENV1, DENV2 and DENV3 infections. Finally, a logistic regression model was constructed using the stats package v.4.2.2 and the oddsratio package v. 2.0.1 in R studio. We assumed a binomial distribution of the response variable to estimate the odds ratio (OR) of developing a subsequent symptomatic versus inapparent infection given an increment of 10^2 in the NT_{50} with a significance level (alpha) of 5%. Power calculations were conducted using the pwr package v. 1.3-0. The package pscl v 1.5.5 was used for estimating the McFadden's pseudo R-squared of each model.

Results

Participants and DENV infections

Our study evaluated pre-infection samples from 127 participants in the Pediatric Dengue Cohort Study (PDCS) in Managua, Nicaragua [24,33]. These samples were collected from 64 participants with subsequent inapparent DENV infection and 63 participants with subsequent symptomatic dengue (Fig.1). Participants were stratified based on their infection history, distinguishing between those who had only one previous infection (primary) and those who had two or more DENV infections (secondary). In the pre-inapparent group, which consisted of individuals protected against dengue disease, 34 individuals had experienced a previous primary infection, while 30 had had secondary infections. Similarly, in the pre-symptomatic group, 41 individuals had experienced a previous primary infection and 22 had had $\geq$2 DENV infections (Table 1).

Confirmation of partially mature and mature viruses

To evaluate the impact of virus maturation state on antibody neutralization, we produced partially mature and mature virions from Nicaraguan DENV1, DENV2, and DENV3 clinical isolates and confirmed maturation state by measuring pr content in each virus stock via Western blot. We detected significant amounts of prM in Vero-grown viruses, indicating a partially mature phenotype (Fig. S1A). Production of the same parental viruses in furin-overexpressing cells significantly increased the maturation state of the virions, as observed by low to undetectable levels of prM (Fig. S1A). Virion maturation state was also assessed by FRNT using anti-FL mAbs (1M7, 4G2, B7) that neutralize partially mature virions better than mature virions[9]. As expected, virions grown in Vero-furin cells required a higher concentration of anti-FL mAbs to be neutralized as compared to virions grown in Vero cells (Fig. S1C-D). Viruses grown in standard and furin-overexpressing Vero cells will be hereafter referred to as "partially mature" and "mature" virions, respectively.

We then assessed viral infectivity of partially mature and mature DENV1, DENV2, and DENV3 on both Vero and DC-SIGN-expressing Vero cells. The infectivity of partially mature and mature virus stocks in standard and DC-SIGN-expressing Vero cells was measured as the ratio of physical particle (vRNA) equivalents to focus forming units (FFU) (Fig. S1B). As expected, the presence of cellular attachment factor DC-SIGN on the surface of Vero cells increased viral infectivity. The lowest infectivity (10^3-10^4 vRNA:FFU) was observed using partially mature virions with Vero cells. Conversely, mature virions with Vero DC-SIGN cells were 10 times more infectious and had the lowest particle-to-FFU ratio (Table S1).

Cell substrate and DENV maturation state impact neutralization titer

Next, we sought to understand how *in vitro* neutralization potency of serum samples varies based on virus and cellular substrate assay conditions. Using the mature and partially mature DENV1, DENV2, and DENV3 virus stocks together with plasma samples collected prior to a subsequent DENV infection (n=127), we evaluated the nAb titers against the incoming serotype (Fig. 1). The four assay conditions included: partially mature DENV with Vero cells, partially mature DENV with Vero DC-SIGN cells, mature DENV with Vero cells, and mature DENV with Vero DC-SIGN cells. Overall, nAb titers were significantly higher in assays performed using partially mature compared to mature virions, as well as in Vero compared to Vero DC-SIGN cells (paired Wilcoxon test; Fig. 2). The largest difference in median NT_{50} was observed between assays performed using Vero cells infected with partially mature virions (reference assay condition, NT_{50}=202) compared to Vero DC-SIGN cells infected with mature virions (NT_{50}=42). Thus, our findings reinforce that increasing virion maturation state and the presence of DC-SIGN significantly decrease the estimation of serum DENV-neutralizing potency.

Neutralizing antibody association with protection is dependent on infection history

We then compared the neutralization potency of pre-inapparent (n=64) versus pre-symptomatic (n=63) DENV infection samples. We observed a significantly higher nAb titer in the pre-inapparent group than in the pre-symptomatic group across all four conditions (Fig. 3A), consistent with our previous studies[6], which supports that higher nAb titers are related to protection from symptomatic dengue.

To further analyze whether the NT_{50} magnitude was associated with lower risk of a subsequent symptomatic DENV infection, we performed a logistic regression model for each assay condition. Consistently, a higher NT_{50} was associated with lower risk of developing a subsequent symptomatic disease for partially mature virions (OR 0.86, 95% Confidence Interval [CI] 0.75-0.96) and mature virions (OR 0.82, 95% CI 0.70-0.94) on Vero cells, as well as for

partially mature virions (OR 0.85, 95% CI 0.73-0.96) and mature virions (OR 0.72, 95% CI 0.53-0.92) on Vero DC-SIGN cells (Table 2). Taken together, these results demonstrated that pre-existing cross-reactive nAb titers are correlated with lower risk of developing a subsequent symptomatic infection.

We next interrogated the impact of infection history on this correlation by stratifying participants by their infection histories. We observed a significantly higher nAb titer in the pre-inapparent group than the pre-symptomatic group among post-primary individuals (n=75) across all four conditions (Fig. 3B). However, no significant difference in nAb titer was observed in the post-secondary group (n=52) (Fig. 3B). Consistently, in the post-primary infection group, the NT_{50} assessed using Vero cells with partially mature virions (OR 0.75, 95% CI 0.58 to 0.93) and mature virions (OR 0.79, 95% CI 0.63 to 0.97), as well as the NT_{50} assessed using Vero DC-SIGN cells with partially mature virions (OR 0.73, 95% CI 0.55 to 0.92) and mature virions (OR 0.31, 95% CI 0.12 to 0.65), were associated with lower risk of subsequent symptomatic infection. Nevertheless, in the post-secondary infection group, none of the NT_{50} titers assessed were associated with protection.

Neutralizing antibody magnitude associates with protection against dengue disease in a serotype-dependent manner

Next, we stratified the analysis by incoming DENV serotype. Our study contained 19 individuals with subsequent post-primary DENV1 infections, 61 individuals with subsequent DENV2 infections, and 47 individuals with subsequent DENV3 infections (Table S1). In the pre-DENV1 infection group (Fig. 4A, top row), which includes only post-primary infection individuals, higher nAb titers were observed in assays with mature virions on Vero cells and partially mature virions on both Vero and Vero DC-SIGN cells in the pre-inapparent group.

In the pre-DENV2 infection group, significantly higher nAb titers were observed in the pre-inapparent individuals across all conditions (Fig. 4A, middle row) when samples were not stratified by infection history. However, after stratification (Fig. 3B), only nAb titers assessed in Vero and Vero DC-SIGN cells using mature virions were correlated with protection from symptomatic infection in the post-primary group (n=29) (OR 0.62, 95% CI 0.38-0.88; OR 0.09 ,95% 0.01-0.52, respectively) and with mature virions in Vero cells in the post-secondary group (n=32) (OR 0.72, 95% CI, 0.5-0.95) (Fig 3B and Table S1).

In contrast, in the pre-DENV3 group (Fig. 4A, bottom row), the magnitude of nAb titers was not significantly different between subsequent symptomatic and inapparent infection regardless of assay condition or infection history (Fig. S2). Overall, these analyses reveal that in our sample set, higher pre-infection nAb titers are associated with protection from symptomatic

DENV1 and DENV2 infection across multiple assay conditions, but they are not associated with protection from symptomatic DENV3 infection.

Assay condition impacts pre-infection cut-off values associated with outcome

Since the identification of a pre-infection cut-off value that helps to identify individuals that will develop symptomatic infection is important for vaccine design, we performed a ROC analysis for comparing the assay conditions in terms of their sensitivity and specificity for detecting subsequent symptomatic infection (Table 2). For our analysis, sensitivity was defined as the proportion of symptomatic infections with NT_{50} titers below the established threshold, while specificity corresponded to the proportion of inapparent infections with NT_{50} titers above this value. We selected an NT_{50} cut-off value for achieving a sensitivity of at least 90%, when possible.

Notably, our findings revealed a substantial impact of assay condition on the determination of the NT_{50} cut-off value. Prior to stratification by infection history, the NT_{50} values varied significantly, ranging from 180 for mature virions on Vero DC-SIGN cells to 898 for partially mature virions on Vero cells (Table 2). Furthermore, even when considering the assay condition with the highest specificity (i.e., mature virions with Vero cells) only 32% of subsequent inapparent infections had a NT_{50} values above the established threshold. When we stratified by infection history, all conditions effectively identified subsequent symptomatic infections in the post-primary infection group, except for mature virions with Vero cells. Notably, mature virions with Vero DC-SIGN displayed the best performance (sensitivity 93% and specificity 35%) among the evaluated conditions (Table 2). This means that when using NT_{50} values calculated with an assay involving mature virions and Vero DC-SIGN cells, 93% of the individuals who later developed symptomatic infection had NT_{50} values below the cut-off.

Maturation state- and DC-SIGN-sensitive antibodies are potential drivers of infection outcome

Given the impact of virion maturation state and cell substrate on NT_{50} performance as a predictor of subsequent symptomatic infection, we wanted to interrogate the possible role of maturation state-sensitive antibodies as drivers of subsequent infection outcome. To investigate whether variations in nAb composition were associated with different outcomes, we compared paired nAb titers across the four assay conditions. Interestingly, we did not observe any significant difference in the magnitude of nAb titers from post-primary pre-*inapparent* infection individuals (i.e., protected) and post-secondary pre-*symptomatic* infection individuals (i.e., not protected) across all four conditions tested (Fig. 5A,B). However, we observed that, in contrast

to the pre-*inapparent* infection group, the neutralization potency of pre-*symptomatic* infection samples was significantly lower using mature virions compared to partially mature virions in Vero cells, as well as when using partially mature virions infecting DC-SIGN-expressing Vero cells compared to Vero cells (Fig. 5C). This result suggests that in our cohort, a higher quantity of nAbs that are maturation state-dependent and sensitive to the expression of DC-SIGN is associated with subsequent symptomatic dengue disease. This result emphasizes the importance of antibody quality in addition to magnitude when studying correlates of protection against dengue disease.

Pre-infection neutralizing antibody composition differentially impacts outcome by DENV serotype and infection history

To assess how variations in nAb composition in pre-infection sera relate to protection from symptomatic DENV infection for each serotype, we used paired Wilcoxon tests to compare the neutralization potency of samples stratified by serotype across assay conditions. In post-primary pre-DENV1, pre-DENV2, and pre-DENV3 symptomatic individuals (Fig. 6A,B,C; Fig. S3), we observed significant differences in NT_{50} titer when FRNT assays were performed using partially mature virions with Vero compared to Vero DC-SIGN cells. These findings indicate that antibodies present in pre-symptomatic infection samples are less potent for neutralizing DENV when cell entry is glycan-mediated (i.e., interacting with DC-SIGN on the target cell). This suggests a difference in antibody repertoire, with pre-symptomatic post-primary DENV infection individuals having less nAbs able to block DC-SIGN-mediated entry.

In contrast, in post-secondary pre-DENV2 infection samples (Fig. 6D), a significant reduction in NT_{50} titer was observed in pre-symptomatic infection samples when FRNT assays were performed in Vero cells using partially mature versus mature DENV2 virions. This suggests a difference in antibody repertoire, with post-secondary pre-symptomatic DENV2 individuals having more nAbs sensitive to maturation state. No difference in nAb quality was observed in post-secondary pre-DENV3 infections.

Discussion

In this study, we analyzed 127 individuals with subsequent inapparent or symptomatic DENV infection from our long-standing cohort in Nicaragua with known infection history. We evaluated the effect of previous primary or secondary DENV immunity on the quantity and quality of the cross-reactive nAb response by controlling key parameters of the neutralization assay. We also assessed the association of nAb titer under different assay conditions with probability of

symptomatic DENV1, DENV2 or DENV3 infection. While we confirmed that nAb titers overall are associated with protection against symptomatic DENV infection[6], we found important differences by infection history (i.e., prior primary versus secondary immunity) and incoming serotype. We also show that the ability of nAb titers to identify individuals at risk depends on DENV maturation state and cellular substrate in the neutralization assay.

Neutralizing antibodies are considered an essential component of the protective response against flavivirus infections and are used to assess vaccine safety and efficacy[34,35]. As a quantitative functional antibody assay, the neutralization assay is considered the "gold standard" for quantifying and characterizing DENV nAbs[7]. However, in routine laboratory practice as well as in clinical trials, it is common to use virions grown in Vero or C6/36 cells, although it has been shown that DENV virions purified directly from human blood or produced in primary cells using monocyte-derived dendritic cells are more mature than virions grown in cell culture-adapted lines[9,36]. To approach a virion state closer to the one observed during natural infection, furin-overexpressing cell lines were generated and used to produce mature flavivirus stocks with low prM content[36,37]. This difference in maturation state changes the proportion and identity of epitopes exposed and, thus, the number and type of antibodies required to completely neutralize infectious particles[10,15]. Consistent with published literature, we observed that plasma samples showed a significantly lower neutralizing activity on mature virions compared to partially mature virions grown in Vero cells, suggesting that neutralization titers may be overestimated under standard FRNT conditions[38].

Glycan-mediated entry is an important aspect of DENV dissemination in humans[39,40], but standard assay conditions using cells lacking C-type lectin receptors (e.g., DC-SIGN) do not measure the contribution of nAbs that prevent N-glycan interactions. Unlike other flaviviruses, the E protein of DENV has an additional glycosylation site at Asp-67 (EDI), which allows DENV to enter cells through interaction with DC-SIGN[16]. As we and others have shown[16], DC-SIGN is a key attachment factor for DENV, and expressing it on the surface of Vero cells significantly increases DENV infectivity. DC-SIGN is expressed on dendritic cells (DCs) and monocytes[17–19] and is associated with DENV pathogenesis. Nevertheless, while nAbs that impede DC-SIGN-mediated viral entry could limit viral dissemination and promote the establishment of a rapid and effective cell-mediated immune response[19], this parameter is rarely considered when studying antibody-mediated protection against dengue disease. In this study, we assessed the effect of DC-SIGN expression on Vero cells to measure nAbs able to block another entry pathway relevant to DENV biology. As expected, nAb titers were strongly affected (decreased) by the expression of DC-SIGN, and the reduction in cross-reactive nAb potency was even greater when assays were performed using mature virions. Similar results were previously

published using another flavivirus closely related to DENV, West Nile virus, together with DC-SIGNR expressing-cells[10]. We found that when mature virions are used with Vero DC-SIGN cells, 90% of the subsequent symptomatic infections can be identified with a lower NT_{50} cutoff than with other assay conditions, particularly in post-primary infections. This shows that more serum antibodies are required to neutralize in *in vitro* assays with more physiologically relevant viruses and cells. Thus, anti-DENV nAb titers are likely overestimated when measured in standard Vero cell-based assays and virions with a maturation state different from the virions that antibodies encounter in the bloodstream during infection. These findings highlight the importance of selecting an appropriate cell substrate and virion maturation state to support vaccine development and evaluate efficacy.

Consistent with previous reports[6], we observed significantly higher nAb titers in participants before an inapparent DENV infection as compared to before a symptomatic DENV infection when analyzing the entire sample set. However, after stratification by post-primary versus post-secondary DENV infection history, we found that the magnitude of the nAb response only significantly correlated with protection after prior primary infection, although the direction of the effect was similar for post-secondary infections. Further, we observed differences in association with infection outcome when stratifying by incoming serotype. Higher magnitude of pre-infection nAb titer was associated with protection from subsequent symptomatic infection with DENV1 or DENV2, but not with DENV3 in any of the assay conditions or infection histories. Interestingly, in a recent study investigating potential additional antibody characteristics that could play a protective role, we found that antibody-dependent complement deposition (ADCD) and complement- and antibody-mediated virolysis were associated with protection from symptomatic disease in samples collected prior to a subsequent DENV3 infection[41]. We also found that, while their nAb titer magnitude was similar, the neutralizing activity of post-secondary pre-symptomatic infection individuals was primarily driven by both DC-SIGN-sensitive and maturation state-dependent Abs, while the neutralizing potency of post-primary pre-inapparent infection was not. This suggests that variations in the composition of the antibody repertoire exist in the protected versus unprotected groups and that a difference in nAb quality might be associated with disease outcome.

In addition, while 90% of the subsequent symptomatic infections in our study had pre-infection NT_{50} titers below the NT_{50} threshold identified via ROC analysis, a substantial proportion of pre-inapparent infection individuals did not reach this cutoff either, yet they did not develop a symptomatic infection. This suggests that although nAbs play a role in protection against symptomatic disease, the magnitude of nAb titers is not a robust parameter to differentiate protected individuals from those at risk of developing a symptomatic infection and

that other components of the immune response may play an even more important role. This suggests that the measurement of other antibody Fc functions such as ADCD or virolysis[41] may serve as correlates of protection, which could be used in addition to neutralization assays toward the design and evaluation of dengue vaccines, as well as other components of the immune response such as T cells.

The strengths of our study include the unique sample set that allowed us to evaluate the effects of neutralization assay condition on the outcome of DENV infection in natural populations. Samples from diverse epidemics allowed us to observe the distinctions in contribution of cross-reactive nAbs to protection from subsequent symptomatic infection depending on infection history and incoming serotype, which have not been reported previously. We also used clinical isolates representing circulating strains in the study population, which is important because highly passaged reference strains are cell line-adapted and have accumulated mutations that can change their antigenic landscape[9]. In contrast, many vaccine studies and research laboratories frequently use WHO reference strains that do not match the genotypic and phenotypic features of the contemporary DENV strains[32,42].

Nevertheless, our study has limitations. First, since we studied sequential DENV infections in natural populations, we evaluated the role of cross-reactive nAbs in protection, but were not able to assess type-specific nAbs, which are often the focus of studies of vaccine efficacy[5]. Nonetheless, many of our findings and overall conclusions are relevant for studies of immune correlates of dengue. Second, as our study population is from Nicaragua over a 15-year period, our analysis is naturally limited to the circulating serotypes and epidemiology of DENV in the timeframe and area of study. Third, although anti-DENV antibodies can also have infection-enhancing properties, we do not measure this here since we focus on studying the neutralizing capacity of antibodies using cell substrates that do not express Fcγ receptors that can mediate antibody-dependent enhancement[43]. Lastly, our current sample size is under-powered for the predictive model of risk of symptomatic disease for incoming DENV1 or DENV3 infection. Nonetheless, the observed differences in effect sizes imply that for achieving a power of at least 80% we would need only 28 pre-DENV1 infection individuals, in contrast with 231 pre-DENV3 infection individuals, as well as a total of 222 individuals in the post-secondary infection group. These differences in the required sample size are evidence of the potential negligible role of nAbs in protection against DENV3 symptomatic infection and upon a post-secondary infection.

In conclusion, we have identified serotype-specific differences in the association of nAbs with protection against symptomatic infection. Higher NT_{50} titers were associated with protection against symptomatic DENV infection in participants with one prior DENV infection, but only

against DENV2 in those with multiple prior infections. nAbs were correlated with protection from symptomatic DENV1 and DENV2 infections but not DENV3. Thus, the unique features of our cohort allowed us to identify the role of the infection history in shaping the protective potency of nAb, as well as the relevance of the incoming serotype, ultimately revealing the heterogeneity and the complexity of immune interactions among DENV serotypes. Comparing different assay conditions, we found that maturation state- and DC-SIGN-sensitive nAbs may be less protective against symptomatic DENV infection. More studies are needed to assess the effects of these variables, as well as the impact of WHO reference strains compared to clinical isolates in the context of vaccine studies. Finally, although nAbs correlate with protection under specific circumstances, our findings reveal that they do not capture the full breadth of the protective immune response, thus implying an important role for other aspects of the antibody and broader immune response in generation and evaluation of protection from symptomatic dengue. Incorporating a broader range of immune parameters in serological assays will enable a more comprehensive evaluation of immune correlates of protection.

Funding

This work was supported by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH) via grant P01AI106695 (E.H.). The PDCS study was supported by NIAID/NIH grants U01AI153416 (E.H.) and U19AI118610 (E.H.), R01AI099631 (A.B.), the Pediatric Dengue Vaccine Initiative grant VE-1 (E.H.) from the Bill and Melinda Gates Foundation, and NIH subcontract HHSN2722001000026C (E.H.). L.C.K. was supported by the Intramural Research Program of NIAID/NIH.

Acknowledgment

We are grateful for the PDCS and HICS participants and their families. We appreciate the hard work and dedication of the past and present members of the study team at the Centro de Salud Sócrates Flores Vivas, the Sustainable Sciences Institute in Nicaragua, and the Laboratorio Nacional de Virología in the Centro Nacional de Diagnóstico y Referencia.

REFERENCES

1. Cattarino, L., Rodriguez-Barraquer, I., Imai, N., Cummings, D. A. T. & Ferguson, N. M. Mapping global variation in dengue transmission intensity. *Sci. Transl. Med.* **12**, (2020).
2. Katzelnick, L. C., Coloma, J. & Harris, E. Dengue: knowledge gaps, unmet needs, and research priorities. *Lancet Infect. Dis.* **17**, e88–e100 (2017).
3. Salje, H. *et al.* Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. *Nature* **557**, 719–723 (2018).
4. Katzelnick, L. C. *et al.* Zika virus infection enhances future risk of severe dengue disease. *Science* **369**, 1123–1128 (2020).
5. Sabchareon, A. *et al.* Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. *Lancet* **380**, 1559–1567 (2012).
6. Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. *Proceedings of the National Academy of Sciences* **113**, 728–733 (2016).
7. Thomas, S. J. *et al.* Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. *Am. J. Trop. Med. Hyg.* **81**, 825–833 (2009).
8. Kuhn, R. J. *et al.* Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. *Cell* **108**, 717–725 (2002).
9. Raut, R. *et al.* Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 227–232 (2019).
10. Mukherjee, S. *et al.* Mechanism and significance of cell type-dependent neutralization of flaviviruses. *J. Virol.* **88**, 7210–7220 (2014).
11. Yu, I.-M. *et al.* Structure of the immature dengue virus at low pH primes proteolytic maturation. *Science* **319**, 1834–1837 (2008).
12. Stadler, K., Allison, S. L., Schalich, J. & Heinz, F. X. Proteolytic activation of tick-borne encephalitis virus by furin. *J. Virol.* **71**, 8475–8481 (1997).
13. Li, L. *et al.* The flavivirus precursor membrane-envelope protein complex: structure and maturation. *Science* **319**, 1830–1834 (2008).
14. Plevka, P. *et al.* Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres. *EMBO Rep.* **12**, 602–606 (2011).
15. Nelson, S. *et al.* Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. *PLoS Pathog.* **4**, e1000060 (2008).
16. Mondotte, J. A., Lozach, P.-Y., Amara, A. & Gamarnik, A. V. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. *J. Virol.* **81**, 7136–7148 (2007).
17. Schmid, M. A., Diamond, M. S. & Harris, E. Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. *Front. Immunol.* **5**, 647 (2014).
18. Hacker, K., White, L. & de Silva, A. M. N-linked glycans on dengue viruses grown in mammalian and insect cells. *J. Gen. Virol.* **90**, 2097–2106 (2009).
19. Rodriguez-Madoz Juan R., Bernal-Rubio Dabeiba, Kaminski Dorota, Boyd Kelley & Fernandez-Sesma Ana. Dengue Virus Inhibits the Production of Type I Interferon in

Primary Human Dendritic Cells. *J. Virol.* **84**, 4845–4850 (2010).
20. Durbin, A. P. *et al.* Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. *Virology* **376**, 429–435 (2008).
21. Hall, W. C. *et al.* Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. *Am. J. Trop. Med. Hyg.* **45**, 408–417 (1991).
22. Jessie, K., Fong, M. Y., Devi, S., Lam, S. K. & Wong, K. T. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. *J. Infect. Dis.* **189**, 1411–1418 (2004).
23. Schmid, M. A. & Harris, E. Monocyte recruitment to the dermis and differentiation to dendritic cells increases the targets for dengue virus replication. *PLoS Pathog.* **10**, e1004541 (2014).
24. Kuan, G. *et al.* The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods, Use of Information Technology, and Extension to Other Infectious Diseases. *Am. J. Epidemiol.* **170**, 120–129 (2009).
25. Gordon, A. *et al.* The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004-2010. *PLoS Negl. Trop. Dis.* **7**, e2462 (2013).
26. Lanciotti, R. S., Calisher, C. H., Gubler, D. J., Chang, G. J. & Vorndam, A. V. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. *J. Clin. Microbiol.* **30**, 545–551 (1992).
27. Waggoner, J. J. *et al.* Homotypic Dengue Virus Reinfections in Nicaraguan Children. *J. Infect. Dis.* **214**, 986–993 (2016).
28. Balmaseda, A., Sandoval, E., Pérez, L., Gutiérrez, C. M. & Harris, E. Application of molecular typing techniques in the 1998 dengue epidemic in Nicaragua. *Am. J. Trop. Med. Hyg.* **61**, 893–897 (1999).
29. Waggoner, J. J. *et al.* Development of an internally controlled real-time reverse transcriptase PCR assay for pan-dengue virus detection and comparison of four molecular dengue virus detection assays. *J. Clin. Microbiol.* **51**, 2172–2181 (2013).
30. Waggoner, J. J. *et al.* Single-Reaction Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. *Emerg. Infect. Dis.* **22**, 1295–1297 (2016).
31. Tse, L. V. *et al.* Generation of Mature DENVs via Genetic Modification and Directed Evolution. *MBio* **13**, e0038622 (2022).
32. Martinez, D. R. *et al.* Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. *Cell Rep.* **33**, 108226 (2020).
33. Katzelnick, L. C. *et al.* Antibody-dependent enhancement of severe dengue disease in humans. *Science* **358**, 929–932 (2017).
34. Dowd, K. A. & Pierson, T. C. Antibody-mediated neutralization of flaviviruses: a reductionist view. *Virology* **411**, 306–315 (2011).
35. Pierson, T. C. & Diamond, M. S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. *Expert Rev. Mol. Med.* **10**, e12 (2008).
36. Dejnirattisai, W. *et al.* A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. *Nat. Immunol.* **16**, 170–177 (2015).
37. Mukherjee, S. *et al.* Enhancing dengue virus maturation using a stable furin over-expressing cell line. *Virology* **497**, 33–40 (2016).

38. Maciejewski, S. *et al.* Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. *Sci. Transl. Med.* **12**, (2020).
39. Idris, F., Muharram, S. H. & Diah, S. Glycosylation of dengue virus glycoproteins and their interactions with carbohydrate receptors: possible targets for antiviral therapy. *Arch. Virol.* **161**, 1751–1760 (2016).
40. Hidari, K. I. P. J. & Suzuki, T. Antiviral agents targeting glycans on dengue virus E-glycoprotein. *Expert review of anti-infective therapy* vol. 9 983–985 (2011).
41. Dias, A. G., Jr *et al.* Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. *Sci. Transl. Med.* **14**, eabm3151 (2022).
42. Gallichotte, E. N., Baric, R. S. & de Silva, A. M. The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections. *Adv. Exp. Med. Biol.* **1062**, 63–76 (2018).
43. Boonnak, K. *et al.* Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. *J. Virol.* **82**, 3939–3951 (2008).

Tables

Table 1. Pre-inapparent and pre-symptomatic infection participant characteristics.

Table 2. ROC analysis and logistic regression of NT_{50} magnitude as a predictor for developing a subsequent symptomatic disease, stratified by infection history.

Figure Legends

Figure 1. Participant serological sampling schematic. Plasma samples from DENV-immune participants were collected before a subsequent DENV1, 2, or 3 infection and were stratified into two separate groups according to disease outcome: Pre-inapparent (blue) and pre-symptomatic (yellow).

Figure 2. Cross-reactive nAb titers across assay conditions. Neutralizing titers (NT_{50}) of 127 participants measured against the incoming DENV serotype using virions of different maturation state and different cell substrate. Median NT_{50} values are indicated below each boxplot. Diamond indicates mean NT_{50}. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test. p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

Figure 3. Cross-reactive nAb titers of pre-inapparent and pre-symptomatic DENV infection participants. (A) NT_{50} of pre-inapparent (n=64) and pre-symptomatic (n=63) DNV infection groups measured against the incoming serotype across FRNT assay conditions, and (B) stratified by infection history (Post-1°: post-primary infection, Post-2°: post-secondary infection). Diamond indicates mean NT_{50}. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test. p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

Figure 4. Cross-reactive nAb titers of pre-inapparent and pre-symptomatic DENV infection participants stratified by incoming serotype and infection history. (A) NT_{50} of pre-inapparent and pre-symptomatic DENV infection groups across FRNT assay conditions stratified by incoming serotype. (B) NT_{50} of pre-DENV2 infection participants stratified by infection history. Diamond indicates mean NT_{50}. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test. p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

Figure 5. Comparison of nAb responses between pre-inapparent post-primary and pre-symptomatic post-secondary participants. (A) Magnitude of the nAb response using different virion maturation states and cell substrates. (B) Impact of change in assay condition on the neutralization titers of pre-inapparent post-primary and pre-symptomatic post-secondary participants. Asterisks indicate Benjamini Hochberg adjusted p-values for Wilcoxon test. p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

Figure 6. Serotype-specific characteristics of the nAb response associated with DENV infection outcome. Impact of change in assay condition on the nAb response of pre-inapparent and pre-symptomatic infection participants from the (A) post-primary pre-DENV1 infection group, (B) post-primary pre-DENV3 infection group, and (C) post-secondary pre-DENV2 infection group. Post-1°: post-primary infection, Post-2°: post-secondary infection. Asterisks indicate Benjamini Hochberg adjusted p-values for paired Wilcoxon tests. p-values: ns, >0.05; *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001.

Table 1

	Pre-inapparent	Pre-symptomatic	p
n	64	63	
Age (mean (SD))	10.66 (2.81)	10.41 (3.56)	0.665
Male (%)	35 (55.6)	37 (60.7)	0.694
Infection history (%)			0.03
Primary (%)	34 (53.1)	41 (65.0)	
Secondary (%)	30 (46.9)	22 (35.0)	

Table 2

	AUC	CI 95	Threshold (NT50)	Sensitivity	Specificity	OR	CI 95
Combined							
Part.Mature Vero	0.642	0.544 to 0.740	898.13	0.94	0.08	0.86	0.75 to 0.96
Mature Vero	0.624	0.525 to 0.723	475.83	0.9	0.32	0.82	0.7 to 0.94
Part.Mature Vero DC-SIGN	0.648	0.550 to 0.746	701.95	0.9	0.14	0.85	0.73 to 0.96
Mature Vero DC-SIGN	0.639	0.542 to 0.736	180.25	0.9	0.29	0.72	0.53 to 0.92
Primary							
Part.Mature Vero	0.682	0.557 to 0.807	392.7	0.9	0.29	0.75	0.58 to 0.93
Mature Vero	0.627	0.496 to 0.759	367.95	0.9	0.26	0.79	0.63 to 0.97
Part.Mature Vero DC-SIGN	0.684	0.560 to 0.808	276.6	0.9	0.32	0.73	0.55 to 0.92
Mature Vero DC-SIGN	0.701	0.582 to 0.821	96.81	0.93	0.35	0.31	0.12 to 0.65
Secondary							
Part.Mature Vero	0.54	0.37 to 0.71	981.84	1	0.1	*ns*	-
Mature Vero	0.59	0.43 to 0.75	767.76	1	0.17	*ns*	-
Part.Mature Vero DC-SIGN	0.56	0.39 to 0.73	891.09	0.95	0.1	*ns*	-
Mature Vero DC-SIGN	0.54	0.38 to 0.7	455.15	0.91	0.21	*ns*	-

AUC = Area under the curve, CI95 = 95% Confidence interval, OR = Odds ratio, Part. Mature = Partially mature virion.

Figure 1


DENV immune
DENV infection
DENV1
DENV2
DENV3
Serum/Plasma sample
Inapparent
Symptomatic

Figure 2


NT50 (log10)
5
4
3
2
1
****
****
ns
****
****
****
202
179
163
42
Vero
Partially Mature
Vero
Mature
Vero DC-SIGN
Partially Mature
Vero DC-SIGN
Mature

Figure 3


A.
Vero
Partially Mature
Vero
Mature
Vero DC-SIGN
Partially Mature
Vero DC-SIGN
Mature
NT50 (log10)
ALL
pre-inapp.
pre-sympt.
B.
Post 1°
Post 2°
ns
pre-
inapp.
pre-
sympt.

Figure 4


A.
Vero
Partially Mature
Vero
Mature
Vero DC-SIGN
Partially Mature
Vero DC-SIGN
Mature
pre-DENV1
pre-DENV2
pre-DENV3
NT50 (log10)
*
***
ns
pre-inapp.
pre-sympt.


B.
Vero
Partially Mature
Vero
Mature
Vero DC-SIGN
Partially Mature
Vero DC-SIGN
Mature
Post 1°
Post 2°
pre-DENV2
NT50 (log10)
*
ns
pre-
inapp.
pre-
sympt.

Figure 5

A.


Prior 1° DENV
Prior 2° DENV
Inap.
Symp.
Inap.
Symp.

B.


Vero
Partially Mature
Vero
Mature
Vero DC-SIGN
Partially Mature
Vero DC-SIGN
Mature
EC50 (log10)
ns
pre-inapp.
Post-1°
pre-sympt.
Post-2°

C.


pre-inapp.
Post-1°
pre-sympt.
Post-2°
EC50 (log10)
****
ns
***
*
**
Part. Mature
Vero
Mature
Vero
Part. Mature
Vero
DC-SIGN
Mature
Vero
DC-SIGN

Figure 6


A.
pre-inapp.
pre-sympt.
ns
**
NT50 (log10)
3
2
1
Part. Mature Vero
Part. Mature Vero DC-SIGN
Post 1° pre-DENV1
B.
pre-inapp.
pre-sympt.
ns
*
Post 1° pre-DENV2
C.
pre-inapp.
pre-sympt.
ns
**
Mature Vero
Mature Vero DC-SIGN
Post 1° pre-DENV3
D.
pre-inapp.
pre-sympt.
ns
**
Part. Mature Vero
Mature Vero
Post 2° pre-DENV2